로딩 중…
StockDiggingStockDigging

Bausch + Lomb Corporation

BLCO· NYSE
CACA
$20.00+0.02%
2026-11-02

Financials

Valuation Metrics

Bausch + Lomb Corporation's Market Cap is $7.13B. At end of 2025 it was $6.04B. Ranked #1087 of 3,115 in US market (top 35%), #735 of 1,643 on NYSE (top 45%), #77 of 203 in Health Care Equipment & Services (top 38%) by Market Cap.

Investment Metrics(as of 2026-11-02)

MetricValue
Size
Market Cap$7.13B
Revenue$5.41B
Net Income$-111M
Total Assets$13.96B
Net Assets$6.44B
Employees13,000
Value
P/B1.11x
P/S1.32x
EV/EBITDA9.72x
FCF Yield3.56%
Profitability
ROE-1.72%
ROA-0.80%
Op. Margin8.41%
Revenue Growth8.78%
Financial Health
Debt Ratio115.69%
Total Debt$45M
FCF$254M
Cash$513M
Current Ratio1.56x
Net Debt/EBITDA-0.68x
Performance
1Y Return33.90%
1M Return16.92%
From 52W High-6.34%
1Y MDD-20.11%
Trading
Volume1,285,212 shares
Trading Value$26M
Per Share
EPS$-0.31
BPS$18.06

Company Info

CEO Brenton L. Saunders
Employees 13,000
HQ Vaughan, CA

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.